Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 5/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 5/20 | 0.37 |
| ▸ | ITGAV | P06756 | 5/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.37 |
| ▸ | ITGA5 | P08648 | 5/20 | 0.37 |
| ▸ | ITGB5 | P18084 | 5/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 5/20 | 0.33 |
| ▸ | PYGL | P06737 | 1/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19485674 | 1.00 | ITGB3 (0.37) | ITGB3ITGB1ITGAVITGA2BITGA5 | |
| SCHEMBL17834943 | 0.92 | ITGB3 (0.39) | ITGB3ITGB1ITGAVITGA2BITGA5 | |
| SCHEMBL17834651 | 0.92 | ENPP2 (0.37) | ITGB3ITGB1ITGAVITGA2BITGA5 | |
| SCHEMBL19485685 | 0.92 | ENPP2 (0.37) | ITGB3ITGB1ITGAVITGA2BITGA5 | |
| SCHEMBL17834817 | 0.91 | ITGB3 (0.40) | ITGB3ITGB1ITGAVITGA2BITGA5 | |
| SCHEMBL19485632 | 0.91 | ITGB3 (0.40) | ITGB3ITGB1ITGAVITGA2BITGA5 | |
| SCHEMBL17834958 | 0.91 | ITGB3 (0.40) | ITGB3ITGB1ITGAVITGA2BITGA5 | |
| SCHEMBL19485742 | 0.91 | ITGB3 (0.40) | ITGB3ITGB1ITGAVITGA2BITGA5 | |
| SCHEMBL17834960 | 0.90 | ITGB1 (0.39) | ITGB3ITGB1ITGAVITGA2BITGA5 | |
| SCHEMBL19485739 | 0.90 | ITGB1 (0.39) | ITGB3ITGB1ITGAVITGA2BITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3230276-B1 | GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-09-02 | — | — | EP | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2018-01-25 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| WO-2016094729-A1 | GLP-1 RECEPTOR MODULATORS | CELGENE INTERNATIONAL II SARL (CH) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | ITGB3 4025/4885ITGB1 3589/4885ITGAV 4625/4885 |
| US-10034886-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | ITGB3 3678/4885ITGB1 3369/4885ITGAV 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.